It is approved for the treatment of adult patients with transfusion-dependent anemia due to MDS-RS and an unsatisfactory response to EPO-based therapy, as well as for adult patients suffering from transfusion-dependent anemia associated with beta-thalassemia (198). The gene discussed is EPO; the disease is myelodysplastic syndrome.